Hints and tips:
Related Special Reports
...Gilead has worked with scientists at Accelerated Clinical Trials Ltd to develop a blood cancer treatment....
...As healthcare systems around the world put pressure on drug prices, pharma companies are also looking for ways to cut costs in research and development....
...Unlike their big pharma cousins, they were better known for operational and financial acumen than cutting edge science....
...Astellas Pharma bought eye-treatment specialist Iveric Bio in a $5.9bn deal in May. Mizuho splashed out $550mn for US boutique investment bank Greenhill & Co....
...Her pay at the family-owned company dwarfs the remuneration offered by listed FTSE 100 groups, where Pascal Soriot, boss of pharma group AstraZeneca, was the highest paid executive in 2022 with annual earnings...
...Clinical trials of the first AI-designed molecule — announced in 2020 by Oxford-based Exscientia and Sumitomo Pharma — were unsuccessful....
...Tighter funding for pharma research means Ergomed’s market is slowing down. Group revenues are expected to grow at 10 per cent this year, down from more than 20 per cent in 2022....
...Japanese pharma group Eisai said new analysis found 60 per cent of patients at the very early stages of Alzheimer’s showed a clinical improvement after taking its drug Leqembi for 18 months, compared to...
...Pascal Soriot, AstraZeneca’s chief executive, said in February that drugmakers should not be made to pay for the “explosion” of NHS costs, while US pharma groups Eli Lilly and AbbVie quit the pricing agreement...
Daiichi Sankyo and AstraZeneca’s Enhertu could double time patients can live without their condition progressing
...Amid expectations of booming demand for fever medicine and other drugs, mainland China-listed shares of pharma companies Guangzhou Baiyunshan Pharmaceutical and Hualan Biological Engineering each gained...
...Big pharma companies distribute medicines and products on a global scale but develop fewer drugs themselves, meaning they invest heavily in biotech to secure their drug pipeline....
...seeks to strike out Mozambique ‘tuna bonds’ case (FT) Sanjeev Gupta’s Australian steel business tests bond investor interest (FT) Croatian government pressed Allianz over €500mn Sberbank deal (FT) Big Pharma...
...Gilead SciencesO: 6; L: 8; I: 7; Total: 21The South Korean legal team at the US-based pharma group increased self-service on legal issues in the rest of the business....
...It caused an estimated $10bn in damages and years of wrangling between companies like pharma group Merck and snack maker Mondelez and their insurers....
...Kevin Gorman, senior vice-president at German pharma giant Merck, a key supplier to the chip industry, says the company’s scientists have been working on PFAS-free alternatives since 2020....
...“The goal of Isomorphic is to produce drugs which we can then partner with pharma to get them out into the clinic and to people with clinical need,” Murdoch said....
...Shares in Biogen and Eisai surged on Wednesday after the pharma groups said they would apply for regulatory approval for a new Alzheimer’s drug following a late-stage clinical trial that showed it slowed...
...As pharma blogger Derek Lowe pointed out, the drug removes plaques but doesn’t slow the disease all that much. Worse, clearing the plaques carries risks....
...The head of pharma company Sanofi said UK economic policy meant the country was falling behind in healthcare innovation....
...UK competition authorities have cut £20mn from a £90mn fine against two pharma companies for overcharging the NHS for a life-saving epilepsy drug, after a long legal battle....
...A key differentiating factor between these groups and Fosun issubsidiary Fosun Pharma....
...He used to be the chief of French pharma giant Sanofi. Millennium Management, the multi-strategy hedge fund, has hired Justin Gmelich from King Street as its new co-chief investment officer....
...Late last year, pharma group Merck succeeded in a US court claim that a war exclusion should not be applied to its losses suffered in the NotPetya malware attack....
...Under a three-year business plan unveiled last month, the company will invest ¥100bn in research and development or to expand factories in the health science and pharma sectors, and ¥80bn in its beer and...
International Edition